On the 30th, Ildong Pharmaceutical announced that it recorded KRW 150.9 billion in revenue and KRW 5 billion in operating profit on a consolidated preliminary basis for the second quarter of 2026.

Compared to the same period last year, revenue and operating profit surged by 9.0% and 739.1%, respectively. However, on a quarter-on-quarter basis, revenue increased by only 6.3%, while operating profit declined by 45.8%.

Key performance indicators for the second quarter are as follows: • Profit from continuing operations before income tax expense: KRW 6.5 billion (turned profitable from a loss in the same period last year; down 29.5% from the previous quarter) • Net income: KRW 8.1 billion (turned profitable from the same period last year; up 10.2% from the previous quarter) • Net income attributable to owners of the parent company: KRW 12.7 billion (turned profitable from the same period last year; up 53.3% from the previous quarter)

On a cumulative first-half basis, the company achieved KRW 292.9 billion in revenue and KRW 14.2 billion in operating profit. Compared to the same period last year, cumulative revenue increased by 6.7% and cumulative operating profit grew by 197.0%. Additionally, cumulative profit from continuing operations before income tax, net income, and net income attributable to owners of the parent company all turned profitable year-on-year.

The company also disclosed its preliminary first-half results based on separate financial statements. Accordingly, it recorded KRW 287.6 billion in revenue, KRW 16.6 billion in operating profit, KRW 11.7 billion in net profit before income tax, and KRW 9.5 billion in net income.

Ildong Pharmaceutical added that these results are consolidated preliminary figures prepared in accordance with the Korean International Financial Reporting Standards (K-IFRS) and may be subject to change depending on the outcome of the external audit, which has not yet been completed.